新型PPARα/γ双重激动剂muraglitazar
被引量：2
摘要
过氧化物酶体增殖物激动受体(PPAR)a/g双重激动剂同时激活PPARa和g,不仅能够改善胰岛素抵抗,而且能治疗脂代谢紊乱。本文就PPARa/g双重激动剂muraglitazar的药理学特性、临床疗效和安全性作简要综述。
出处
《世界临床药物》
CAS
2006年第12期744-747,共4页
World Clinical Drug
参考文献9
-
1.
-
2.
-
3.
-
4Buse JB,Rubin CJ,Frederich R,et al.Muraglitazar,a dual(alpha/gamma)PPAR activator:a randomized,double-blind,placebo-controlled,24-week monotherapy trial in adult patients with type2diabetes[].Clinical Therapeutics.2005
-
5Harrity T,Farrelly D,Tieman A,et al.Muraglitazar,a novel dual(alpha/gamma)peroxisome proliferator-activated receptor activator,improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice[].Diabetes.2006
-
6Staels B,Fruchart JC.Therapeutic roles of peroxisome proliferator-activated receptor agonists[].Diabetes.2005
-
7Nissen SE,Wolski K,Topol EJ.Effect of muraglitazar on death and major adverse cardiovascular events inpatients with type2diabetes mellitus[].The Journal of The American Medical Association.2005
-
8Frick MH,Elo O,Haapa K,et al.Helsinki Heart Study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia Safety of treatment,changes in risk factors,and incidence of coronary heart disease[].The New England Journal of Medicine.1987
-
9Brunzell JD,Ayyobi AF.Dyslipidemia in the metabolic syndrome and type2diabetes mellitus[].The American Journal of Medicine.2003
同被引文献36
-
1王学玲.诺和龙和拜糖平治疗以餐后血糖升高为主的2型糖尿病疗效观察[J].中国误诊学杂志,2009,9(3):587-588. 被引量：3
-
2杨帆,张学军.2型糖尿病药物治疗新进展[J].实用医院临床杂志,2010,7(4):19-21. 被引量：7
-
3阮园,沈建国.胰淀素类似物普兰克林治疗糖尿病的研究进展[J].国外医学（内科学分册）,2005,32(12):507-509. 被引量：2
-
4张莹芳.糖尿病治疗药物的现状及进展[J].海峡药学,2006,18(2):7-11. 被引量：15
-
5黄建权,傅得兴,胡欣,张君仁.抗糖尿病药物维达列汀[J].中国新药杂志,2007,16(6):486-488. 被引量：11
-
6叶任高,陆再英.内科学[M].第6版.北京:人民卫生出版社,2006:787-788.
-
7叶任高.陈灏珠.内科学.第6版.北京:人民卫生出版社.2006.281
-
8Intensive blood - glucose control with sulphonylureas or insulin com- pared with conventional treatment and risk of complications in pa- tients with type 2 diabetes ( UKPDS 33 ). UK Prospective Diabetes Study(UKPDS) Group. Lancet, 1998 ;352(9131 ) :837.
-
9Bregenhoh S, Moldrup A, Blume N, et al. The long-acting glu- cagon - like peptide - 1 analogue, liraglutide, inhibits beta - cell apoptosis in vitro. Biochem Biophys Res Commun, 2005;330:577.
-
10US Food and Drug Administration. Exenatide( marketed as Byetta)Information. Aug, 18, 2008 http://www, fda. gov/cder/drug/in- fopage/exenatide/defauh, htm( accessed Aug 27,2008 ).
-
1杨俊,邹秀兰.PPARα/γ双重激动剂与2型糖尿病[J].医学综述,2008,14(16):2492-2496. 被引量：2
-
2Robert R Henry Prof A Michael Lincoff Sunder iudaliar.SYNCHRONY研究：PPAR—α/γ双重激动剂对2型糖尿病心血管风险的作用[J].中国处方药,2009(8):30-30.
-
3本刊编辑部.PPARγ、α双受体激动剂muraglitazar每日5mg疗效优于pioglitazone每日30mg[J].中华糖尿病杂志（1006-6187）,2005,13(4):320-320.
-
4史婷婷,庄让笑,周红萍,王福根,邵益丹,蔡兆斌.芹菜素对大鼠非酒精性脂肪性肝炎肝组织过氧化物酶体增殖物激活受体表达的影响[J].中华肝脏病杂志,2015,23(2):124-129. 被引量：8
-
5陈凌,郭若冰,戴军.氯吡格雷在缺血性心血管疾病防治中的作用[J].中国新药杂志,2000,9(10):718-721. 被引量：36
-
6卞如濂.吸入型糖皮质激素的药理学特性[J].中国实用儿科杂志,2000,15(7):440-441. 被引量：74
-
7李燕燕.Merck／BMS共同进行muraglitazar的Ⅲ期临床[J].国外药讯,2004(8):13-13.
-
8田中直樹,姚月歌.过氧化物酶体增殖物激活受体[J].日本医学介绍,2007,28(4):154-156. 被引量：4
-
9周建敏,牛雪花,姚国卫.吡格列酮对2型糖尿病患者糖脂代谢及C反应蛋白的影响[J].山西医药杂志（上半月）,2009,38(6):567-568. 被引量：1
-
10Steven,E.,Nissen,Kathy,Wolski,Eric,J.,Topol,沈琴（译）,贾伟平（校）.Muragntazar对2型糖尿病患者死亡及主要心血管不良事件的影响[J].美国医学会杂志（中文版）,2006,25(6):366-366. 被引量：1
